Hepatitis C Virus is considered to be the principal etiologic agent responsible for 90-95% of the cases of posttransfusion non-A and non-B hepatitis. Approximately 170 million people worldwide are chronically infected with HCV. But only 20% patents can be diagnosed. As a blood-borne virus, HCV can be transmitted by blood and blood products. So early diagnosis is very important. HCV PCR Fluorescence Quantitative Diagnostic kit combines the technologies of nucleic acid amplification and probe to detect HCV RNA.
HCV RNA is reverse transcribed and a specific fragment is amplified with specific primers in a one-step RT-PCR reaction. The products are detected by using a specific Taqman-MGB Probe.